Storia in 3 fonti

Treatment Intensification Slows Metastatic Hormone-Sensitive Prostate Cancer

Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alterations

Raccontata da

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo3 mesi fa

Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alterations

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer